# A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

> **NCT00406419** · PHASE3 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 1015 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00406419
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12-27
- **Primary completion:** 2009-10-06
- **Final completion:** 2015-04-22
- **Target enrollment:** 1015 (ACTUAL)
- **Why stopped:** Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
- **Last updated:** 2020-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406419, "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00406419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*